Literature DB >> 16496415

Loss of PTEN is associated with progression to androgen independence.

Jerod Bertram1, James W Peacock, Ladan Fazli, Alice L-F Mui, Stephen W Chung, Michael E Cox, Brett Monia, Martin E Gleave, Christopher J Ong.   

Abstract

BACKGROUND: Progression to a lethal androgen-independent (AI) stage of advanced prostate cancer is a critical clinical obstacle limiting patient survival. PTEN inactivation is frequently observed in advanced prostate cancer and correlates with a poor prognosis. However, the functional significance of PTEN inactivation in AI progression has not been demonstrated.
METHODS: PTEN expression was examined in benign, hormone naïve and AI human prostate cancer specimens, and in recurrent AI Shionogi tumors. The effect of antisense oligonucleotide (ASO)-mediated PTEN downregulation in AI progression of the Shionogi tumor model was determined.
RESULTS: Significantly reduced PTEN expression was observed in AI versus benign and hormone naïve prostate tumors. Seven of 14 AI Shionogi tumors exhibited marked downregulation or complete loss of PTEN. ASO-mediated PTEN inhibition reduced androgen-withdrawal induced regression of Shionogi tumors and accelerated AI progression.
CONCLUSIONS: These data suggest that PTEN inactivation may play a role in progression to androgen independence. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496415     DOI: 10.1002/pros.20411

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  30 in total

Review 1.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

Review 2.  Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.

Authors:  Marxa L Figueiredo; Makoto Sato; Mai Johnson; Lily Wu
Journal:  Future Oncol       Date:  2006-06       Impact factor: 3.404

3.  Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.

Authors:  Jake Higgins; Michele Brogley; Nallasivam Palanisamy; Rohit Mehra; Michael M Ittmann; Jun Z Li; Scott A Tomlins; Diane M Robins
Journal:  Horm Cancer       Date:  2015-01-29       Impact factor: 3.869

4.  Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.

Authors:  Muhan Chen; Dawid G Nowak; Lloyd C Trotman
Journal:  Clin Cancer Res       Date:  2014-06-15       Impact factor: 12.531

Review 5.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

Review 6.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Authors:  Jaclyn LoPiccolo; Gideon M Blumenthal; Wendy B Bernstein; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2007-12-31       Impact factor: 18.500

7.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.

Authors:  Bo Han; Rohit Mehra; Robert J Lonigro; Lei Wang; Khalid Suleman; Anjana Menon; Nallasivam Palanisamy; Scott A Tomlins; Arul M Chinnaiyan; Rajal B Shah
Journal:  Mod Pathol       Date:  2009-05-01       Impact factor: 7.842

8.  Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.

Authors:  Lu Gan; Shuai Chen; Yuwei Wang; Akira Watahiki; Laura Bohrer; Zhen Sun; Yuzhuo Wang; Haojie Huang
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

9.  Pathogenesis of prostate cancer and hormone refractory prostate cancer.

Authors:  J S Girling; H C Whitaker; I G Mills; D E Neal
Journal:  Indian J Urol       Date:  2007-01

10.  Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.

Authors:  B G Barwick; M Abramovitz; M Kodani; C S Moreno; R Nam; W Tang; M Bouzyk; A Seth; B Leyland-Jones
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.